BENVYON 25 MG
BENDAMUSTINE HYDROCHLORIDE : 25 MG · DIN 02524309 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is BENVYON?
BENVYON 25 MG contains BENDAMUSTINE HYDROCHLORIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02524309, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 30-Jan-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BENVYON used for?
BENVYON (Bendamustine Hydrochloride for Injection) is indicated for treatment of patients with: • Relapsed indolent B-cell non-Hodgkin lymphoma (NHL) who did not respond to or progressed during or shortly following treatment with a rituximab regimen. • Symptomatic chronic lymphocytic leukemia (CLL) who have received no prior treatment.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02524309 |
|---|---|
| Brand name | BENVYON |
| Generic / active ingredient | BENDAMUSTINE HYDROCHLORIDE : 25 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 25 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01AA09 BENDAMUSTINE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Jan-2023 |
| Original market date | 2023-01-30 00:00:00 |
How is it stored and handled?
2 °C – 8 °C
How is it supplied?
25 mg/1 mL (2 mL amber glass vials) – Single-use; 100 mg/4 mL (5 mL amber glass vials) – Multidose; 200 mg/8 mL (10 mL amber glass vials) – Multidose
Is BENDAMUSTINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 21 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01AA09 BENDAMUSTINE. 11 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02496860 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02542005 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02509261 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02509253 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02496852 |
| BENDAMUSTINE HYDROCHLORIDE FOR INJECTION | 25 MG | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02541998 |
| NAT-BENDAMUSTINE | 100 MG | POWDER FOR SOLUTION | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02496895 |
| NAT-BENDAMUSTINE | 25 MG | POWDER FOR SOLUTION | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02496887 |
| TREANDA | 100 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02392569 |
| TREANDA | 25 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02392550 |
Who else supplies BENDAMUSTINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BENDAMUSTINE appears in 80 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.